Kefort

Active Ingredient:: Ibandronic Acid
Origin:: EU

Kefort (Ibandronic Acid)

Q: What is Kefort used for?

Kefort contains ibandronic acid, a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women and men, as well as for managing Paget's disease of bone. In these conditions it helps increase bone mineral density and reduces the risk of fractures or abnormal bone turnover.

Q: How does ibandronic acid work?

Ibandronic acid binds to bone mineral surfaces and, when osteoclasts attach, it is taken up and inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway. This blocks prenylation of small GTP‑binding proteins, impairing osteoclast formation, activity and survival, thereby decreasing bone resorption.

Q: What is the usual dose of Kefort?

The dosage of Kefort is determined individually by a qualified prescriber based on the patient's clinical condition, renal function and other factors. Patients should follow the prescribing information and take the medication exactly as instructed by their healthcare professional.

Q: Is Kefort safe during pregnancy or breastfeeding?

Safety of ibandronic acid in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their doctor.

Q: How do I order Kefort from GNH India?

To request Kefort, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The team then replies with pricing, availability, shipping details and any required import documentation.

Q: How does Kefort compare with other bisphosphonates?

Kefort (ibandronate) is a potent bisphosphonate taken orally, typically once monthly, whereas agents like alendronate or risedronate are often dosed weekly. Ibandronate has a longer dosing interval and may be preferred for patients seeking less frequent administration, but efficacy and safety profiles are comparable across the class.

Q: How should Kefort be stored?

Kefort tablets should be stored at below 25 °C (room temperature) in their original packaging, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Q: How is Kefort administered?

Kefort is taken orally with a full glass of plain water on an empty stomach, at least 30 minutes before the first food, drink, or other medication of the day. After swallowing, remain upright for at least 30 minutes to reduce the risk of esophageal irritation.

Q: What are the most serious risks associated with Kefort?

The most serious adverse events include osteonecrosis of the jaw, atypical femur fractures, severe esophagitis, acute renal impairment, and clinically significant hypocalcemia. Patients should be monitored for these conditions and instructed to report any persistent jaw pain, unusual thigh pain, or swallowing difficulties promptly.

Q: Who should not use Kefort?

Kefort is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min), known hypersensitivity to ibandronate or other bisphosphonates, active esophageal disorders that delay emptying, or those unable to remain upright after dosing. Caution is also advised for patients with low calcium levels or those on certain interacting medications.

Ibandronic Acid, the active ingredient in Kefort, is a bisphosphonate presented as an oral tablet for oral use. It treats osteoporosis and Paget's disease of bone in adult patients and is indicated for the management of postmenopausal osteoporosis, male osteoporosis, and for reducing bone turnover in Paget's disease.

GNH India supplies Kefort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU Good Manufacturing Practice and provides regulatory‑approved products to healthcare providers across global markets.

Manufacturer / TM Owner

Bausch Health Ireland Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Kefort (ibandronic acid) is used in conditions affecting bone remodeling and density.
Osteoporosis (postmenopausal women): improves bone mineral density and reduces fracture risk.
Osteoporosis (men): increases bone strength and lowers fracture incidence.
Paget's disease of bone: normalizes abnormal bone turnover and alleviates bone pain.

How It Works

Ibandronic acid belongs to the bisphosphonate class and binds to hydroxyapatite crystals on bone surfaces. When osteoclasts attach to bone, the drug is internalized and inhibits the enzyme farnesyl pyrophosphate synthase within the mevalonate pathway, disrupting prenylation of small GTP‑binding proteins. This impairs osteoclast formation, activity and survival, leading to reduced bone resorption and a net gain in bone mineral density.

Side Effects

Oral ibandronic acid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

Abdominal pain
Nausea
Dyspepsia
Musculoskeletal pain

Serious or Rare Side Effects

Osteonecrosis of the jaw
Atypical femur fracture
Severe esophagitis

Precautions & Warnings

Before initiating therapy, several safety considerations should be observed.

Assess renal function: evaluate creatinine clearance to ensure suitability.
Ensure adequate calcium and vitamin D intake: supplement as needed to maintain normal levels.
Avoid concomitant oral bisphosphonates: reduces risk of cumulative toxicity.
Monitor for esophageal irritation: advise patients to remain upright after dosing.
Review use of NSAIDs or steroids: may increase gastrointestinal risk.
Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Ibandronic acid can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

Antacids or supplements containing calcium, magnesium, aluminum, or iron taken within 2 hours: markedly reduces ibandronate absorption.
Concomitant use with other bisphosphonates: increases risk of cumulative toxicity.
Severe renal impairment (eGFR < 30 mL/min): contraindicated due to accumulation risk.

Moderate Interactions (Monitor Closely)

Calcium supplements (timing separate by ≥2 hours).
Vitamin D analogs (may enhance calcium effects).
Corticosteroids (increase risk of osteoporosis).
Warfarin (potential alteration of INR).
Diuretics (affect calcium balance).

Frequently Asked Questions

Kefort contains ibandronic acid, a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women and men, as well as for managing Paget's disease of bone. In these conditions it helps increase bone mineral density and reduces the risk of fractures or abnormal bone turnover.

Ibandronic acid binds to bone mineral surfaces and, when osteoclasts attach, it is taken up and inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway. This blocks prenylation of small GTP‑binding proteins, impairing osteoclast formation, activity and survival, thereby decreasing bone resorption.

The dosage of Kefort is determined individually by a qualified prescriber based on the patient's clinical condition, renal function and other factors. Patients should follow the prescribing information and take the medication exactly as instructed by their healthcare professional.

Safety of ibandronic acid in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their doctor.

To request Kefort, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The team then replies with pricing, availability, shipping details and any required import documentation.

Kefort (ibandronate) is a potent bisphosphonate taken orally, typically once monthly, whereas agents like alendronate or risedronate are often dosed weekly. Ibandronate has a longer dosing interval and may be preferred for patients seeking less frequent administration, but efficacy and safety profiles are comparable across the class.

Kefort tablets should be stored at below 25 °C (room temperature) in their original packaging, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Kefort is taken orally with a full glass of plain water on an empty stomach, at least 30 minutes before the first food, drink, or other medication of the day. After swallowing, remain upright for at least 30 minutes to reduce the risk of esophageal irritation.

The most serious adverse events include osteonecrosis of the jaw, atypical femur fractures, severe esophagitis, acute renal impairment, and clinically significant hypocalcemia. Patients should be monitored for these conditions and instructed to report any persistent jaw pain, unusual thigh pain, or swallowing difficulties promptly.

Kefort is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min), known hypersensitivity to ibandronate or other bisphosphonates, active esophageal disorders that delay emptying, or those unable to remain upright after dosing. Caution is also advised for patients with low calcium levels or those on certain interacting medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.